secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-001984
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio appoints Robert Lisicki as President/COO and Kiran Nistala as CMO; CMO Chris Cabell departs
--------------------------------------------------------------------------------

- Chris Cabell steps down as Chief Medical Officer and EVP effective Jan 15, 2024; no disagreement with management.
- Robert Lisicki appointed President and COO effective Jan 8; base salary $440,000 with 40% target bonus and 1M options grant.
- Kiran Nistala joins as EVP Development and CMO; previously VP Immunology at AstraZeneca and roles at GSK.
- Lisicki brings experience from Arena Pharmaceuticals (acquired by Pfizer) and Regeneron; Nistala from GSK and AstraZeneca.
- Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924001984/0001104659-24-001984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924001984/tm242343d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-001984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer